首页 > 最新文献

Minerva Urology and Nephrology最新文献

英文 中文
The value of 3D printing model combined PCNL in kidney stones: a systematic review and meta-analysis. 三维打印模型联合 PCNL 在肾结石中的价值:系统综述和荟萃分析。
IF 4.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-08-01 DOI: 10.23736/S2724-6051.24.05720-3
Guo Y Ai, Zhen Zhou, Zhicong Huang, Jian Zhong, Shusheng Liu, Weijie Liu, Xuliang Pang, Wei Zhu

Introduction: With the continuous advancement of medical imaging, 3D printing technology is emerging. This technology allows for the representation of complex objects in a model form. This research aims to delve into the irreplaceable value of percutaneous nephrolithotomy (PCNL) in conjunction with 3D printed models in urinary stone surgery. This forward-looking approach provides doctors with a new perspective, enabling them to plan and execute surgeries with greater precision, ultimately delivering a safer and more efficient treatment experience for patients. We evaluated the literature on PCNL for the kidney stones with the introduction of 3D printing models and conducted a meta-analysis. The assessed parameters included stone clearance rate, operation time, hospital stay, blood loss, puncture accuracy, and the rate of complications.

Evidence acquisition: We systematically searched the EMBASE, PubMed, Cochrane Library, SCIE, and Chinese Biomedical Literature Search databases for articles related to PCNL (Percutaneous Nephrolithotomy) with 3D printing models from January 2000 to January 2023. Data were managed and screened using Excel . Meta-analysis was performed for operation time, stone clearance rate, blood loss, puncture accuracy, length of hospital stay, and complications in PCNL combined with 3D printing model for kidney stone treatment. The quality of included articles was assessed using the risk of bias tool by the Cochrane Collaboration. Sensitivity analysis was conducted to assess the reliability of the results. Data were recorded using StataSE 17 software, and publication bias was examined using Egger's linear regression test.

Evidence synthesis: We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines to conduct a systematic search and screening of literature relevant to the use of 3D printed models in the treatment of kidney stones. We conducted an extensive literature search across several major academic databases, including EMBASE, PubMed, Cochrane Library, SCIE, and Chinese Biomedical Literature Search databases, to ensure comprehensive coverage of relevant studies. Following the PRISMA process of screening and analysis, we ultimately included 10 randomized controlled trials with a combined sample of 608 for systematic review.

Conclusions: Across these studies, we identified the introduction of 3D printing models prior to surgery for kidney stones resulted in significant advantages for the experimental group compared to the control group in terms of operation time, stone clearance rates, puncture accuracy, hospital stay, blood loss, and the incidence of complications, providing valuable insights for further research and clinical practice.

简介随着医学成像技术的不断进步,3D 打印技术应运而生。这项技术可以将复杂的物体以模型的形式表现出来。本研究旨在深入探讨经皮肾镜取石术(PCNL)与 3D 打印模型在泌尿结石手术中不可替代的价值。这种前瞻性的方法为医生提供了新的视角,使他们能够更精确地规划和实施手术,最终为患者带来更安全、更高效的治疗体验。我们评估了引入 3D 打印模型的 PCNL 治疗肾结石的文献,并进行了荟萃分析。评估参数包括结石清除率、手术时间、住院时间、失血量、穿刺准确性和并发症发生率:我们在 EMBASE、PubMed、Cochrane Library、SCIE 和中文生物医学文献检索数据库中系统检索了 2000 年 1 月至 2023 年 1 月与 PCNL(经皮肾镜取石术)和 3D 打印模型相关的文章。数据使用 Excel 进行管理和筛选。对 PCNL 结合 3D 打印模型治疗肾结石的手术时间、结石清除率、失血量、穿刺准确性、住院时间和并发症进行了 Meta 分析。纳入文章的质量由 Cochrane 协作组织使用偏倚风险工具进行评估。为评估结果的可靠性,还进行了敏感性分析。使用StataSE 17软件记录数据,并使用Egger线性回归测试检验发表偏倚:我们遵循PRISMA(系统综述和荟萃分析首选报告项目)指南,对使用3D打印模型治疗肾结石的相关文献进行了系统检索和筛选。我们在多个主要学术数据库中进行了广泛的文献检索,包括 EMBASE、PubMed、Cochrane Library、SCIE 和中文生物医学文献检索数据库,以确保相关研究的全面覆盖。按照 PRISMA 筛选和分析流程,我们最终纳入了 10 项随机对照试验进行系统性审查,合计样本为 608 个:在这些研究中,我们发现在肾结石手术前引入3D打印模型可使实验组在手术时间、结石清除率、穿刺准确性、住院时间、失血量和并发症发生率等方面明显优于对照组,为进一步研究和临床实践提供了有价值的见解。
{"title":"The value of 3D printing model combined PCNL in kidney stones: a systematic review and meta-analysis.","authors":"Guo Y Ai, Zhen Zhou, Zhicong Huang, Jian Zhong, Shusheng Liu, Weijie Liu, Xuliang Pang, Wei Zhu","doi":"10.23736/S2724-6051.24.05720-3","DOIUrl":"10.23736/S2724-6051.24.05720-3","url":null,"abstract":"<p><strong>Introduction: </strong>With the continuous advancement of medical imaging, 3D printing technology is emerging. This technology allows for the representation of complex objects in a model form. This research aims to delve into the irreplaceable value of percutaneous nephrolithotomy (PCNL) in conjunction with 3D printed models in urinary stone surgery. This forward-looking approach provides doctors with a new perspective, enabling them to plan and execute surgeries with greater precision, ultimately delivering a safer and more efficient treatment experience for patients. We evaluated the literature on PCNL for the kidney stones with the introduction of 3D printing models and conducted a meta-analysis. The assessed parameters included stone clearance rate, operation time, hospital stay, blood loss, puncture accuracy, and the rate of complications.</p><p><strong>Evidence acquisition: </strong>We systematically searched the EMBASE, PubMed, Cochrane Library, SCIE, and Chinese Biomedical Literature Search databases for articles related to PCNL (Percutaneous Nephrolithotomy) with 3D printing models from January 2000 to January 2023. Data were managed and screened using Excel . Meta-analysis was performed for operation time, stone clearance rate, blood loss, puncture accuracy, length of hospital stay, and complications in PCNL combined with 3D printing model for kidney stone treatment. The quality of included articles was assessed using the risk of bias tool by the Cochrane Collaboration. Sensitivity analysis was conducted to assess the reliability of the results. Data were recorded using StataSE 17 software, and publication bias was examined using Egger's linear regression test.</p><p><strong>Evidence synthesis: </strong>We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines to conduct a systematic search and screening of literature relevant to the use of 3D printed models in the treatment of kidney stones. We conducted an extensive literature search across several major academic databases, including EMBASE, PubMed, Cochrane Library, SCIE, and Chinese Biomedical Literature Search databases, to ensure comprehensive coverage of relevant studies. Following the PRISMA process of screening and analysis, we ultimately included 10 randomized controlled trials with a combined sample of 608 for systematic review.</p><p><strong>Conclusions: </strong>Across these studies, we identified the introduction of 3D printing models prior to surgery for kidney stones resulted in significant advantages for the experimental group compared to the control group in terms of operation time, stone clearance rates, puncture accuracy, hospital stay, blood loss, and the incidence of complications, providing valuable insights for further research and clinical practice.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":"76 4","pages":"389-398"},"PeriodicalIF":4.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141762598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A systematic review and meta-analysis of the placebo effect on both semen quality and male infertility. 对精液质量和男性不育的安慰剂效应进行系统回顾和荟萃分析。
IF 4.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-08-01 DOI: 10.23736/S2724-6051.24.05559-9
Elvira Utigalieva, Andrey Morozov, Ohad Shoshany, Aleksandr Suvorov, Mark Taratkin, Celeste Manfredi, Marco Falcone, Evgeny Bezrukov, Harun Fajkovic, Giorgio I Russo, Dmitry Enikeev

Introduction: Placebo influence on such objective indicators, as sperm quality and infertility, has not been studied previously, but some studies report that placebo may distort even objective outcomes. The aim of current study is to assess the placebo effect on fertility in patients suffering from sperm abnormalities and/or infertility.

Evidence acquisition: We conducted a search of two databases (Scopus and MEDLINE) and identified placebo-controlled clinical trials which focused on sperm abnormalities and/or male infertility treatment. Primary outcomes included changes in semen parameters (volume, total count, sperm concentration in semen, progressive motility, morphology (normal cells)). Secondary outcomes included DNA fragmentation and change in pregnancy rate.

Evidence synthesis: Seventy-seven articles published from 1983 to 2022 were included. Statistically significant changes were observed for the following values: total sperm count, mean change 0.16 (95% CI 0.05, 0.26); P=0.004, I2=75.1%; and progressive motility, mean change 0.13 (95% CI 0.02, 0.24); P=0.026, I2=84.9%. In contrast, placebo did not affect sperm concentration, sperm volume, sperm morphology or DNA fragmentation index. The publication bias for all the values measured with Egger's test and funnel plots was low.

Conclusions: The current meta-analysis indicated a statistically significant increase of total sperm count and progressive motility in the placebo group. In contrast, placebo did not affect sperm concentration, sperm volume, sperm morphology and DNA fragmentation index. These findings should be considered while planning or analyzing placebo-controlled clinical trials.

介绍:此前尚未研究过安慰剂对精子质量和不育症等客观指标的影响,但一些研究报告称,安慰剂甚至可能扭曲客观结果。本研究旨在评估安慰剂对精子异常和/或不育症患者生育力的影响:我们对两个数据库(Scopus 和 MEDLINE)进行了检索,并确定了安慰剂对照临床试验,这些试验主要针对精子异常和/或男性不育症的治疗。主要结果包括精液参数的变化(体积、总计数、精液中的精子浓度、进行性活力、形态(正常细胞))。次要结果包括 DNA 片段和怀孕率的变化:纳入了从 1983 年到 2022 年发表的 77 篇文章。观察到以下数值有统计学意义的变化:总精子数,平均变化0.16(95% CI 0.05,0.26);P=0.004,I2=75.1%;进行性活力,平均变化0.13(95% CI 0.02,0.24);P=0.026,I2=84.9%。相比之下,安慰剂对精子浓度、精子体积、精子形态或DNA碎片指数没有影响。用Egger检验和漏斗图测量的所有数值的发表偏倚都很低:目前的荟萃分析表明,安慰剂组的精子总数和精子活力有显著的统计学增长。相比之下,安慰剂对精子浓度、精子体积、精子形态和 DNA 破碎指数没有影响。在计划或分析安慰剂对照临床试验时,应考虑这些研究结果。
{"title":"A systematic review and meta-analysis of the placebo effect on both semen quality and male infertility.","authors":"Elvira Utigalieva, Andrey Morozov, Ohad Shoshany, Aleksandr Suvorov, Mark Taratkin, Celeste Manfredi, Marco Falcone, Evgeny Bezrukov, Harun Fajkovic, Giorgio I Russo, Dmitry Enikeev","doi":"10.23736/S2724-6051.24.05559-9","DOIUrl":"10.23736/S2724-6051.24.05559-9","url":null,"abstract":"<p><strong>Introduction: </strong>Placebo influence on such objective indicators, as sperm quality and infertility, has not been studied previously, but some studies report that placebo may distort even objective outcomes. The aim of current study is to assess the placebo effect on fertility in patients suffering from sperm abnormalities and/or infertility.</p><p><strong>Evidence acquisition: </strong>We conducted a search of two databases (Scopus and MEDLINE) and identified placebo-controlled clinical trials which focused on sperm abnormalities and/or male infertility treatment. Primary outcomes included changes in semen parameters (volume, total count, sperm concentration in semen, progressive motility, morphology (normal cells)). Secondary outcomes included DNA fragmentation and change in pregnancy rate.</p><p><strong>Evidence synthesis: </strong>Seventy-seven articles published from 1983 to 2022 were included. Statistically significant changes were observed for the following values: total sperm count, mean change 0.16 (95% CI 0.05, 0.26); P=0.004, I<sup>2</sup>=75.1%; and progressive motility, mean change 0.13 (95% CI 0.02, 0.24); P=0.026, I<sup>2</sup>=84.9%. In contrast, placebo did not affect sperm concentration, sperm volume, sperm morphology or DNA fragmentation index. The publication bias for all the values measured with Egger's test and funnel plots was low.</p><p><strong>Conclusions: </strong>The current meta-analysis indicated a statistically significant increase of total sperm count and progressive motility in the placebo group. In contrast, placebo did not affect sperm concentration, sperm volume, sperm morphology and DNA fragmentation index. These findings should be considered while planning or analyzing placebo-controlled clinical trials.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":"76 4","pages":"423-435"},"PeriodicalIF":4.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141762593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Urologists' proficiency in various donor nephrectomy approaches: a real-life survey, systematic review, and meta-analysis of randomized controlled trials. 泌尿科医生对各种供体肾切除术方法的熟练程度:随机对照试验的实际调查、系统回顾和荟萃分析。
IF 4.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-08-01 DOI: 10.23736/S2724-6051.24.05789-6
Ahmed Eissa, Natali Rodriguez Peñaranda, Marco Ticonosco, Stefano Resca, Adele Piro, Marco Amato, Stefania Ferretti, Ahmed Elsherbiny, Abdelhamid El-Bahnasy, Ahmed Zoeir, Ayman Hagras, Ali Abdel Raheem, Ugo Boggi, Lucrezia Furian, Angelo Territo, Yasser Farahat, Giampaolo Bianchi, Selçuk Güven, Stefano Puliatti, Ali Gozen, Salvatore Micali

Introduction: Donor nephrectomy (DN) is a unique surgical procedure in urological practice, as it involves exposing a healthy individual to the potential risks of surgery. This type of surgery exhibits heterogeneity in terms of approach (open, laparoscopic, or robotic), each with its unique set of advantages and disadvantages. Consequently, there is currently a lack of universally agreed upon clear guidelines. In these settings, this study aims to evaluate transplantation surgeons' knowledge through a real-life survey and compare it with data from published randomized controlled trials (RCTs).

Evidence acquisition: The study is divided into two parts, with the first part focusing on the outcomes of the real-life survey designed to assess surgeons' knowledge about different DN approaches and their real-world practices during the surgery. The second part involves a systematic review and meta-analysis of RCTs, specifically examining the outcomes of different surgical approaches to DN. The systematic review followed the PRISMA Guidelines and involved a search of PubMed and Web of Science for RCTs comparing the outcomes of different DN approaches. The risk of bias was assessed using the RoB-2 tool. The random effect model was mainly used to assess the mean difference of the included studies.

Evidence synthesis: The study was conducted between July 2021 and January 2022 and surveyed 50 surgeons, of which 35 participants (70%) completed the survey. Regarding various approaches to DN, 97.14% of surgeons reported having experience with live DN, and 45.72% performed over 15 cases per year. The most performed approach was pure laparoscopic DN (68.57%). Pure laparoscopic DN was the preferred approach for 77.42% of respondents. The review process resulted in 335 articles, of which 35 were eligible for inclusion in the systematic review. In summary, most studies found that laparoscopic approaches, including standard, hand-assisted, LESS-DN, and mini-LDN, resulted in less postoperative pain, better cosmetic, and quicker recovery times compared to open approaches. The main limitation of the current study is the heterogeneity of the included studies.

Conclusions: The study provides valuable insights into the practices of renal transplantation surgeons, offering a comprehensive comparison to level 1 studies (RCTs) in the field. It underscores the continued significance of ODN in contemporary practice, particularly in light of recommendations from the EAU guidelines on renal transplantation. This reaffirms the need to consider the advantages and disadvantages of various approaches, including factors such as cost, postoperative pain, and cosmetic outcomes. While robotic-assisted DN holds promise, their adoption remains variable, potentially due to limited robust evidence.

简介:供体肾切除术(DN)是泌尿外科实践中一种独特的外科手术,因为它需要将健康人暴露在手术的潜在风险之下。这类手术的方法(开腹、腹腔镜或机器人)各不相同,各有其独特的优缺点。因此,目前缺乏普遍认同的明确指南。在这种情况下,本研究旨在通过实际调查评估移植外科医生的知识,并将其与已发表的随机对照试验(RCT)数据进行比较:本研究分为两部分,第一部分侧重于实际调查的结果,旨在评估外科医生对不同 DN 方法的了解程度以及他们在手术过程中的实际操作。第二部分是对研究性临床试验进行系统综述和荟萃分析,专门研究不同的 DN 手术方法的结果。该系统性综述遵循《PRISMA 指南》,在 PubMed 和 Web of Science 上搜索比较不同 DN 方法疗效的 RCT。采用 RoB-2 工具对偏倚风险进行了评估。随机效应模型主要用于评估纳入研究的平均差异:该研究在 2021 年 7 月至 2022 年 1 月期间进行,调查了 50 名外科医生,其中 35 名参与者(70%)完成了调查。关于DN的各种方法,97.14%的外科医生表示有活体DN的经验,45.72%的外科医生每年进行15例以上的手术。采用最多的方法是纯腹腔镜 DN(68.57%)。77.42%的受访者首选纯腹腔镜 DN 方法。综述过程共收到 335 篇文章,其中 35 篇符合纳入系统综述的条件。总之,大多数研究发现,与开腹方法相比,腹腔镜方法(包括标准方法、手辅助方法、LESS-DN 方法和迷你腹腔镜方法)可减少术后疼痛、改善外观和缩短恢复时间。本研究的主要局限性在于所纳入研究的异质性:本研究为肾移植外科医生的实践提供了有价值的见解,与该领域的一级研究(RCT)进行了全面比较。它强调了ODN在当代实践中的持续重要性,特别是考虑到EAU肾移植指南的建议。这再次证明有必要考虑各种方法的优缺点,包括成本、术后疼痛和美容效果等因素。虽然机器人辅助肾移植技术前景广阔,但其采用情况仍不尽相同,这可能是由于有力的证据有限。
{"title":"Urologists' proficiency in various donor nephrectomy approaches: a real-life survey, systematic review, and meta-analysis of randomized controlled trials.","authors":"Ahmed Eissa, Natali Rodriguez Peñaranda, Marco Ticonosco, Stefano Resca, Adele Piro, Marco Amato, Stefania Ferretti, Ahmed Elsherbiny, Abdelhamid El-Bahnasy, Ahmed Zoeir, Ayman Hagras, Ali Abdel Raheem, Ugo Boggi, Lucrezia Furian, Angelo Territo, Yasser Farahat, Giampaolo Bianchi, Selçuk Güven, Stefano Puliatti, Ali Gozen, Salvatore Micali","doi":"10.23736/S2724-6051.24.05789-6","DOIUrl":"10.23736/S2724-6051.24.05789-6","url":null,"abstract":"<p><strong>Introduction: </strong>Donor nephrectomy (DN) is a unique surgical procedure in urological practice, as it involves exposing a healthy individual to the potential risks of surgery. This type of surgery exhibits heterogeneity in terms of approach (open, laparoscopic, or robotic), each with its unique set of advantages and disadvantages. Consequently, there is currently a lack of universally agreed upon clear guidelines. In these settings, this study aims to evaluate transplantation surgeons' knowledge through a real-life survey and compare it with data from published randomized controlled trials (RCTs).</p><p><strong>Evidence acquisition: </strong>The study is divided into two parts, with the first part focusing on the outcomes of the real-life survey designed to assess surgeons' knowledge about different DN approaches and their real-world practices during the surgery. The second part involves a systematic review and meta-analysis of RCTs, specifically examining the outcomes of different surgical approaches to DN. The systematic review followed the PRISMA Guidelines and involved a search of PubMed and Web of Science for RCTs comparing the outcomes of different DN approaches. The risk of bias was assessed using the RoB-2 tool. The random effect model was mainly used to assess the mean difference of the included studies.</p><p><strong>Evidence synthesis: </strong>The study was conducted between July 2021 and January 2022 and surveyed 50 surgeons, of which 35 participants (70%) completed the survey. Regarding various approaches to DN, 97.14% of surgeons reported having experience with live DN, and 45.72% performed over 15 cases per year. The most performed approach was pure laparoscopic DN (68.57%). Pure laparoscopic DN was the preferred approach for 77.42% of respondents. The review process resulted in 335 articles, of which 35 were eligible for inclusion in the systematic review. In summary, most studies found that laparoscopic approaches, including standard, hand-assisted, LESS-DN, and mini-LDN, resulted in less postoperative pain, better cosmetic, and quicker recovery times compared to open approaches. The main limitation of the current study is the heterogeneity of the included studies.</p><p><strong>Conclusions: </strong>The study provides valuable insights into the practices of renal transplantation surgeons, offering a comprehensive comparison to level 1 studies (RCTs) in the field. It underscores the continued significance of ODN in contemporary practice, particularly in light of recommendations from the EAU guidelines on renal transplantation. This reaffirms the need to consider the advantages and disadvantages of various approaches, including factors such as cost, postoperative pain, and cosmetic outcomes. While robotic-assisted DN holds promise, their adoption remains variable, potentially due to limited robust evidence.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":"76 4","pages":"399-422"},"PeriodicalIF":4.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141762599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The grade of systemic inflammation, immune inhibition, and gut dysbiosis as prognostic factors for bladder cancer recurrence: a metabolomics approach. 作为膀胱癌复发预后因素的全身炎症、免疫抑制和肠道菌群失调的等级:代谢组学方法。
IF 4.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-07-01 DOI: 10.23736/S2724-6051.24.05747-1
Greta Petrella, Giorgia Ciufolini, Sara Lentini, Francesco Montorsi, Andrea Salonia, Massimo Pieri, Simone Albisinni, Riccardo Vago, Daniel Oscar Cicero

Background: The risk of recurrence for non-muscle invasive bladder cancer (NMIBC) is high, and the current methods of predicting it rely on clinical and histopathological markers. Personalized risk assessment can be improved by including new prognostic biomarkers. Our research explores the potential of urinary metabolomics to predict cancer recurrence in NMIBC patients within three years.

Methods: Fifty NMIBC patients were included in the study. Urine samples were collected at diagnosis and before TUR-BT. After three years, patients were classified as relapsed or non-relapsed. An NMR-based metabolomics approach was used to measure the concentration of 44 metabolites in the urine of these patients at the time of their diagnosis. This method provides a comprehensive view of many urinary compounds potentially valuable for discriminating relapsing from non-relapsing patients. The measured metabolic profiles were analyzed through multivariate analysis, probability ROC curves, and Mann-Whitney tests.

Results: Seven metabolites were involved in NMIBC recurrence prediction. We interpret their alteration as the consequence of three main events: gut dysbiosis, systemic inflammation, and immune inhibition. Since these compounds have already been proposed for BC diagnosis, what distinguishes their role as prognostic or diagnostic is the grade of their alteration. Limitations: small sample size; further research to confirm urinary compounds' correlation with physiological processes.

Conclusions: This study exploits urinary metabolic profiles to predict NMIBC recurrence. Specific metabolites are found to be significantly related to cancer relapse. The study highlights the grade of inflammation, immune suppression, and gut dysbiosis in predicting cancer recurrence.

背景:非肌层浸润性膀胱癌(NMIBC)的复发风险很高,目前的预测方法主要依赖于临床和组织病理学标志物。通过纳入新的预后生物标志物,可以改善个性化风险评估。我们的研究探讨了尿液代谢组学预测 NMIBC 患者三年内癌症复发的潜力:研究纳入了 50 名 NMIBC 患者。方法:研究纳入了 50 名 NMIBC 患者,在诊断时和 TUR-BT 前收集尿液样本。三年后,患者被分为复发和未复发。采用基于核磁共振的代谢组学方法测量了这些患者确诊时尿液中 44 种代谢物的浓度。这种方法能全面了解尿液中许多化合物的情况,对区分复发和非复发患者具有潜在价值。通过多变量分析、概率 ROC 曲线和曼-惠特尼检验对所测得的代谢谱进行了分析:结果:七种代谢物参与了 NMIBC 复发预测。我们将这些代谢物的变化解释为三个主要事件的结果:肠道菌群失调、全身炎症和免疫抑制。由于这些化合物已被提议用于乳腺癌诊断,因此它们作为预后或诊断作用的区别在于其改变的等级。局限性:样本量小;需进一步研究证实尿液化合物与生理过程的相关性:本研究利用尿液代谢图谱预测 NMIBC 复发。研究发现,特定代谢物与癌症复发密切相关。该研究强调了炎症、免疫抑制和肠道菌群失调在预测癌症复发中的作用。
{"title":"The grade of systemic inflammation, immune inhibition, and gut dysbiosis as prognostic factors for bladder cancer recurrence: a metabolomics approach.","authors":"Greta Petrella, Giorgia Ciufolini, Sara Lentini, Francesco Montorsi, Andrea Salonia, Massimo Pieri, Simone Albisinni, Riccardo Vago, Daniel Oscar Cicero","doi":"10.23736/S2724-6051.24.05747-1","DOIUrl":"https://doi.org/10.23736/S2724-6051.24.05747-1","url":null,"abstract":"<p><strong>Background: </strong>The risk of recurrence for non-muscle invasive bladder cancer (NMIBC) is high, and the current methods of predicting it rely on clinical and histopathological markers. Personalized risk assessment can be improved by including new prognostic biomarkers. Our research explores the potential of urinary metabolomics to predict cancer recurrence in NMIBC patients within three years.</p><p><strong>Methods: </strong>Fifty NMIBC patients were included in the study. Urine samples were collected at diagnosis and before TUR-BT. After three years, patients were classified as relapsed or non-relapsed. An NMR-based metabolomics approach was used to measure the concentration of 44 metabolites in the urine of these patients at the time of their diagnosis. This method provides a comprehensive view of many urinary compounds potentially valuable for discriminating relapsing from non-relapsing patients. The measured metabolic profiles were analyzed through multivariate analysis, probability ROC curves, and Mann-Whitney tests.</p><p><strong>Results: </strong>Seven metabolites were involved in NMIBC recurrence prediction. We interpret their alteration as the consequence of three main events: gut dysbiosis, systemic inflammation, and immune inhibition. Since these compounds have already been proposed for BC diagnosis, what distinguishes their role as prognostic or diagnostic is the grade of their alteration. Limitations: small sample size; further research to confirm urinary compounds' correlation with physiological processes.</p><p><strong>Conclusions: </strong>This study exploits urinary metabolic profiles to predict NMIBC recurrence. Specific metabolites are found to be significantly related to cancer relapse. The study highlights the grade of inflammation, immune suppression, and gut dysbiosis in predicting cancer recurrence.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141472574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of a structured rehabilitation program on urinary continence in patients with intermediate high-risk prostate cancer undergoing robotic-assisted laparoscopic prostatectomy. 结构化康复计划对接受机器人辅助腹腔镜前列腺切除术的中高危前列腺癌患者排尿持续性的影响。
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-06-01 Epub Date: 2024-05-31 DOI: 10.23736/S2724-6051.24.05848-8
Pier P Avolio, Vittorio Fasulo, Giovanni Lughezzani, Cesare Saitta, Marco Paciotti, Roberto Gatti, Filippo Russo, Maria V Fantacci, Massimo Lazzeri, Davide Maffei, Luisa Pasini, Alberto Saita, Rodolfo Hurle, Paolo Casale, Nicolò M Buffi
{"title":"Impact of a structured rehabilitation program on urinary continence in patients with intermediate high-risk prostate cancer undergoing robotic-assisted laparoscopic prostatectomy.","authors":"Pier P Avolio, Vittorio Fasulo, Giovanni Lughezzani, Cesare Saitta, Marco Paciotti, Roberto Gatti, Filippo Russo, Maria V Fantacci, Massimo Lazzeri, Davide Maffei, Luisa Pasini, Alberto Saita, Rodolfo Hurle, Paolo Casale, Nicolò M Buffi","doi":"10.23736/S2724-6051.24.05848-8","DOIUrl":"10.23736/S2724-6051.24.05848-8","url":null,"abstract":"","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":" ","pages":"384-387"},"PeriodicalIF":4.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141180968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of venous thromboembolism before open or minimally-invasive radical cystectomy in the USA: insurance claims data on perioperative outcomes and healthcare costs. 美国开放式或微创根治性膀胱切除术前静脉血栓栓塞的影响:围手术期结果和医疗成本的保险理赔数据。
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-06-01 DOI: 10.23736/S2724-6051.24.05699-4
Francesco Del Giudice, Anas Tresh, Shufeng Li, Satvir Basran, Sophia G Prendiville, Federico Belladelli, Ettore DE Berardinis, Vincenzo Asero, Carlo M Scornajenghi, Dalila Carino, Matteo Ferro, Bernardo Rocco, Gian Maria Busetto, Ugo Falagario, Riccardo Autorino, Felice Crocetto, Biagio Barone, Benjamin Pradere, Wojciech Krajewski, Łukasz Nowak, Tomasz Szydełko, Marco Moschini, Andrea Mari, Simone Crivellaro, Francesco Porpiglia, Cristian Fiori, Daniele Amparore, Renate Pichler, Abhay Rane, Benjamin Challacombe, Rajesh Nair, Benjamin I Chung

Background: The relationship between venous thromboembolism (VTE) and solid malignancy has been established over the decades. With rising projected rates of bladder cancer (BCa) worldwide as well as increasing number of patients experiencing BCa and VTE, our aim is to assess the impact of a preoperative VTE diagnosis on perioperative outcomes and health-care costs in BCa cases undergoing radical cystectomy (RC).

Methods: Patients ≥18 years of age with BCa diagnosis and undergoing open or minimally invasive (MIS) RC were identified in the Merative™ Marketscan® Research Databases between 2007 and 2021. The association of previous VTE history with 90-day complication rates, postoperative VTE events, rehospitalization, and total hospital costs (2021 USA dollars) was determined by multivariable logistic regression modeling adjusted for patient and perioperative confounders. Sensitivity analysis on VTE degree of severity (i.e., pulmonary embolism [PE] and/or peripheral deep venous thrombosis [DVT]) was also examined.

Results: Out of 8759 RC procedures, 743 (8.48%) had a previous positive history for any VTE including 245 (32.97%) PE, 339 (45.63%) DVT and 159 (21.40%) superficial VTE. Overall, history of VTE before RC was strongly associated with almost any worse postoperative outcomes including higher risk for any and apparatus-specific 90-days postoperative complications (odds ratio [OR]: 1.21, 95% CI, 1.02-1.44). Subsequent incidence of new VTE events (OR: 7.02, 95% CI: 5.93-8.31), rehospitalization (OR: 1.25, 95% CI: 1.06-1.48), other than home/self-care discharge status (OR: 1.53, 95% CI: 1.28-1.82), and higher health-care costs related to the RC procedure (OR: 1.43, 95% CI: 1.22-1.68) were significantly associated with a history of VTE.

Conclusions: Preoperative VTE in patients undergoing RC significantly increases morbidity, post-procedure VTE events, hospital length of stay, rehospitalizations, and increased hospital costs. These findings may help during the BCa counseling on risks of surgery and hopefully improve our ability to mitigate such risks.

背景:几十年来,静脉血栓栓塞症(VTE)与实体恶性肿瘤之间的关系已经确立。随着全球膀胱癌(BCa)预计发病率的上升以及经历过 BCa 和 VTE 的患者人数的增加,我们的目的是评估术前 VTE 诊断对接受根治性膀胱切除术(RC)的 BCa 病例的围手术期结果和医疗费用的影响:2007年至2021年期间,在Merative™ Marketscan®研究数据库中发现了年龄≥18岁、确诊为BCa并接受开腹或微创(MIS)RC手术的患者。通过多变量逻辑回归模型确定了既往 VTE 病史与 90 天并发症发生率、术后 VTE 事件、再次住院和住院总费用(2021 年美元)的关系,并对患者和围手术期混杂因素进行了调整。还对 VTE 严重程度(即肺栓塞和/或外周深静脉血栓形成)进行了敏感性分析:在 8759 例急诊手术中,743 例(8.48%)既往有任何 VTE 阳性病史,包括 245 例(32.97%)肺栓塞、339 例(45.63%)深静脉血栓和 159 例(21.40%)浅表 VTE。总体而言,RC 前的 VTE 病史与几乎所有较差的术后结果密切相关,包括术后 90 天内出现任何并发症和器械特异性并发症的风险较高(几率比 [OR]:1.21,95% CI,1.02-1.44)。新的 VTE 事件的后续发生率(OR:7.02,95% CI:5.93-8.31)、再次住院(OR:1.25,95% CI:1.06-1.48)、非家庭/自理出院状态(OR:1.53,95% CI:1.28-1.82)以及与 RC 手术相关的更高医疗费用(OR:1.43,95% CI:1.22-1.68)均与 VTE 病史显著相关:结论:接受 RC 手术的患者术前出现 VTE 会明显增加发病率、术后 VTE 事件、住院时间、再次住院和住院费用。这些发现可能有助于在 BCa 咨询过程中了解手术风险,并有望提高我们降低此类风险的能力。
{"title":"The impact of venous thromboembolism before open or minimally-invasive radical cystectomy in the USA: insurance claims data on perioperative outcomes and healthcare costs.","authors":"Francesco Del Giudice, Anas Tresh, Shufeng Li, Satvir Basran, Sophia G Prendiville, Federico Belladelli, Ettore DE Berardinis, Vincenzo Asero, Carlo M Scornajenghi, Dalila Carino, Matteo Ferro, Bernardo Rocco, Gian Maria Busetto, Ugo Falagario, Riccardo Autorino, Felice Crocetto, Biagio Barone, Benjamin Pradere, Wojciech Krajewski, Łukasz Nowak, Tomasz Szydełko, Marco Moschini, Andrea Mari, Simone Crivellaro, Francesco Porpiglia, Cristian Fiori, Daniele Amparore, Renate Pichler, Abhay Rane, Benjamin Challacombe, Rajesh Nair, Benjamin I Chung","doi":"10.23736/S2724-6051.24.05699-4","DOIUrl":"https://doi.org/10.23736/S2724-6051.24.05699-4","url":null,"abstract":"<p><strong>Background: </strong>The relationship between venous thromboembolism (VTE) and solid malignancy has been established over the decades. With rising projected rates of bladder cancer (BCa) worldwide as well as increasing number of patients experiencing BCa and VTE, our aim is to assess the impact of a preoperative VTE diagnosis on perioperative outcomes and health-care costs in BCa cases undergoing radical cystectomy (RC).</p><p><strong>Methods: </strong>Patients ≥18 years of age with BCa diagnosis and undergoing open or minimally invasive (MIS) RC were identified in the Merative™ Marketscan<sup>®</sup> Research Databases between 2007 and 2021. The association of previous VTE history with 90-day complication rates, postoperative VTE events, rehospitalization, and total hospital costs (2021 USA dollars) was determined by multivariable logistic regression modeling adjusted for patient and perioperative confounders. Sensitivity analysis on VTE degree of severity (i.e., pulmonary embolism [PE] and/or peripheral deep venous thrombosis [DVT]) was also examined.</p><p><strong>Results: </strong>Out of 8759 RC procedures, 743 (8.48%) had a previous positive history for any VTE including 245 (32.97%) PE, 339 (45.63%) DVT and 159 (21.40%) superficial VTE. Overall, history of VTE before RC was strongly associated with almost any worse postoperative outcomes including higher risk for any and apparatus-specific 90-days postoperative complications (odds ratio [OR]: 1.21, 95% CI, 1.02-1.44). Subsequent incidence of new VTE events (OR: 7.02, 95% CI: 5.93-8.31), rehospitalization (OR: 1.25, 95% CI: 1.06-1.48), other than home/self-care discharge status (OR: 1.53, 95% CI: 1.28-1.82), and higher health-care costs related to the RC procedure (OR: 1.43, 95% CI: 1.22-1.68) were significantly associated with a history of VTE.</p><p><strong>Conclusions: </strong>Preoperative VTE in patients undergoing RC significantly increases morbidity, post-procedure VTE events, hospital length of stay, rehospitalizations, and increased hospital costs. These findings may help during the BCa counseling on risks of surgery and hopefully improve our ability to mitigate such risks.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":"76 3","pages":"320-330"},"PeriodicalIF":4.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141452139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Urinary PSA-ZINC biomarker outperforms standard of care in early detection of prostate cancer. 尿 PSA-ZINC 生物标记物在早期检测前列腺癌方面优于标准疗法。
IF 4.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-06-01 Epub Date: 2024-06-12 DOI: 10.23736/S2724-6051.24.05783-5
Daniele Amparore, Sabrina DE Cillis, Stefano Granato, Michele Ortenzi, Marcello Della Corte, Michele Sica, Alberto Piana, Paolo Verri, Stefano DE Luca, Matteo Manfredi, Cristian Fiori, Giulio Mengozzi, Enrico Bergamaschi, Giuseppe Mariella, Sergio Occhipinti, Francesco Porpiglia

Background: Urine is a promising biological fluid for prostate cancer (PCa) diagnostics due to its non-invasive collection and wide range of biomarkers. The aim of this study was to assess the role of urinary PSA (uPSA) and urinary Zinc (uZinc) as biomarkers for the diagnosis of PCa in combination with routine parameters of standard of care (SOC - blood PSA, abnormal DRE, age) and MRI in patients candidates for prostate biopsy.

Methods: Urine samples after prostatic massages were collected from men with suspected PCa scheduled for prostate biopsy. Quantification of uPSA was performed by ECLIA platform and confirmed by ELISA assay, while uZinc measurement was evaluated by ICP-MS and confirmed by colorimetric in vitro assay. Six multivariate logistic regression analysis were performed to assess diagnostic performance of uPSA and uZinc (urine), SOC and MRI alone, and combination of MRI+SOC, MRI+urine and SOC+MRI+urine. The discriminative power of the logistic models was assessed by calculating the area under the receiver operating characteristic (ROC) curves (AUC).

Results: Two hundred thirty-eight patients were included in the analysis; 145 of them were diagnosed with PCa. Urine test showed a better discrimination of HS from CP, in respect of uPSA and uZinc alone, both for PCa of any grade and Gleason Score ≥7 (4+3) (AUC 0.804 and 0.823 respectively). ROC curve combining SOC+MRI+urine showed an AUC=0.882, that is statistically different from SOC or MRI alone, or MRI+SOC (P=0.0001, P=0.0001, and P=0.008 respectively). PCa risk algorithm designed considering SOC+MRI+urine results in potential reduction of 57% of unnecessary biopsies compared to the current standard parameters.

Conclusions: The loss of uPSA and Zinc production and secretion during neoplastic transformation of the prostate could potentially represent a hallmark of PCa. Its combination with age, PSA and DRE, as well as with mpMRI could represent an interesting approach to improve the diagnostic accuracy of PCa.

背景:尿液因其无创采集和广泛的生物标志物而成为前列腺癌(PCa)诊断中一种前景广阔的生物液体。本研究的目的是评估尿 PSA(uPSA)和尿锌(uZinc)作为生物标志物,结合常规护理标准参数(SOC - 血液 PSA、异常 DRE、年龄)和 MRI,在前列腺活检候选患者中诊断 PCa 的作用:方法:从计划进行前列腺活检的疑似 PCa 患者中收集前列腺按摩后的尿液样本。uPSA的定量采用ECLIA平台,并通过ELISA测定法进行确认;uZinc的测定采用ICP-MS进行评估,并通过比色体外测定法进行确认。对uPSA和u锌(尿液)、SOC和MRI单独以及MRI+SOC、MRI+尿液和SOC+MRI+尿液组合的诊断性能进行了六次多变量逻辑回归分析。通过计算接收者操作特征曲线(ROC)下面积(AUC)来评估逻辑模型的判别能力:分析共纳入 238 名患者,其中 145 人被确诊为 PCa。对于任何级别的 PCa 和 Gleason 评分≥7(4+3)的 PCa,尿液检测显示,单独使用 uPSA 和 uZinc 更能区分 HS 和 CP(AUC 分别为 0.804 和 0.823)。结合 SOC+MRI+urine 的 ROC 曲线显示,AUC=0.882,与单独使用 SOC 或 MRI 或 MRI+SOC 有统计学差异(分别为 P=0.0001、P=0.0001 和 P=0.008)。与目前的标准参数相比,考虑 SOC+MRI+ 尿液的 PCa 风险算法可减少 57% 的不必要活检:结论:在前列腺肿瘤性转化过程中,uPSA 和锌的生成和分泌丧失可能是 PCa 的标志。它与年龄、前列腺特异性抗原(PSA)和前列腺特异性增强指数(DRE)以及 mpMRI 的结合可能是提高 PCa 诊断准确性的有趣方法。
{"title":"Urinary PSA-ZINC biomarker outperforms standard of care in early detection of prostate cancer.","authors":"Daniele Amparore, Sabrina DE Cillis, Stefano Granato, Michele Ortenzi, Marcello Della Corte, Michele Sica, Alberto Piana, Paolo Verri, Stefano DE Luca, Matteo Manfredi, Cristian Fiori, Giulio Mengozzi, Enrico Bergamaschi, Giuseppe Mariella, Sergio Occhipinti, Francesco Porpiglia","doi":"10.23736/S2724-6051.24.05783-5","DOIUrl":"10.23736/S2724-6051.24.05783-5","url":null,"abstract":"<p><strong>Background: </strong>Urine is a promising biological fluid for prostate cancer (PCa) diagnostics due to its non-invasive collection and wide range of biomarkers. The aim of this study was to assess the role of urinary PSA (uPSA) and urinary Zinc (uZinc) as biomarkers for the diagnosis of PCa in combination with routine parameters of standard of care (SOC - blood PSA, abnormal DRE, age) and MRI in patients candidates for prostate biopsy.</p><p><strong>Methods: </strong>Urine samples after prostatic massages were collected from men with suspected PCa scheduled for prostate biopsy. Quantification of uPSA was performed by ECLIA platform and confirmed by ELISA assay, while uZinc measurement was evaluated by ICP-MS and confirmed by colorimetric in vitro assay. Six multivariate logistic regression analysis were performed to assess diagnostic performance of uPSA and uZinc (urine), SOC and MRI alone, and combination of MRI+SOC, MRI+urine and SOC+MRI+urine. The discriminative power of the logistic models was assessed by calculating the area under the receiver operating characteristic (ROC) curves (AUC).</p><p><strong>Results: </strong>Two hundred thirty-eight patients were included in the analysis; 145 of them were diagnosed with PCa. Urine test showed a better discrimination of HS from CP, in respect of uPSA and uZinc alone, both for PCa of any grade and Gleason Score ≥7 (4+3) (AUC 0.804 and 0.823 respectively). ROC curve combining SOC+MRI+urine showed an AUC=0.882, that is statistically different from SOC or MRI alone, or MRI+SOC (P=0.0001, P=0.0001, and P=0.008 respectively). PCa risk algorithm designed considering SOC+MRI+urine results in potential reduction of 57% of unnecessary biopsies compared to the current standard parameters.</p><p><strong>Conclusions: </strong>The loss of uPSA and Zinc production and secretion during neoplastic transformation of the prostate could potentially represent a hallmark of PCa. Its combination with age, PSA and DRE, as well as with mpMRI could represent an interesting approach to improve the diagnostic accuracy of PCa.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":" ","pages":"340-350"},"PeriodicalIF":4.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141307400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The digital era of pediatric urological clinical care: telemedicine for management of lower urinary tract symptoms and nocturnal enuresis - a comprehensive tertiary center insight. 儿科泌尿科临床护理的数字化时代:远程医疗治疗下尿路症状和夜间遗尿症--一家综合性三级中心的见解。
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-06-01 DOI: 10.23736/S2724-6051.24.05846-4
Elisa Cerchia, Marcello Della Corte, Cristian Fiori, Martina Mandaletti, Elena Ruggiero, Massimo Catti, Simona Gerocarni Nappo

Background: Lower urinary tract symptoms (LUTS) and nocturnal enuresis (NE) are complex conditions requiring a long-term follow-up. Telemedicine is an emerging technological tool in the surgical field, and its availability exponentially grew during the COVID-19 pandemic, expanding its application fields, optimizing technical aspects, reducing costs, and ensuring high-quality standards. This work describes our experience with telemedicine in a Division of Pediatric Urology for the follow-up of enuresis and LUTS.

Methods: A retrospective analysis of our telemedicine preliminary experience was conducted at Regina Margherita Children's Hospital in Turin, Italy. This study included all the patients aged <18 years who were monitored for enuresis and LUTS through telemedicine between September 1, 2021 and July 31, 2023. Clinical data and outcomes were analyzed, and patients and families were asked to voluntary fill an evaluation questionnaire on their satisfaction. Additionally, we focused on the post COVID-19 period, between September 2022 and July 2023, analyzing the data of two different patients' populations: the first one (G1) of patients choosing telemedicine outpatients visits (TOVs) and the second one (G2) of those choosing a face-to-face visit.

Results: One hundred five patients were enrolled. One hundred sixty-two TOVs were performed. The median age at first visit was 9.7±0.66 years (range 7-16 years). Diagnosis were: 77/105 (67%) NE and 28/105 (33%) LUTS. The average referred distance between the patients' residence and the hospital was 46.35±129.37 km (range 2-1300 kilometers) and the time taken to overcome it was 44.21±77.29 minutes (range 10-780 minutes). In 64/105 cases (61%) the follow-up was interrupted for total healing or symptoms resumption. Only two cases (2%) required the conversion to an in-person ambulatory consult, due to a social-linguistic barrier. 146/162 families (90%) filled the survey questionnaire at the end of each TOV, reporting in 94% of cases a high satisfaction level. In the comparative statistical analysis of the two patient groups, G1 (52 telemedicine office visits, [TOVs]) vs. G2 (25 face-to-face visits), the average referred distance was 17.78±7.98 km (range: 5-35 km) for G1, contrasting with 7.04±3.35 km (range: 2.5-14 km) for G2 (P=0.00001). Additionally, the waiting time before the visit was 3.96±2.90 minutes (range: 0-10 minutes) for G1, in contrast to 26.52±11.22 minutes (range: 5-44 minutes) for G2 (P=0.00001). Furthermore, a higher compliance with behavioral or pharmacological indications was observed in the G1 group, exhibiting lower adherence in only 12 out of 52 cases compared to 14 out of 25 cases in G2 (P=0.0091).

Conclusions: Telemedicine is a proper solution and an effective tool to manage the therapeutic follow-up of NE and LUTS, ensuring suitable quality standards and reducing social costs, such as the loss of

背景:下尿路症状(LUTS)和夜间遗尿症(NE)是需要长期随访的复杂病症。远程医疗是外科领域的新兴技术手段,在 COVID-19 大流行期间,其可用性呈指数增长,扩大了其应用领域,优化了技术方面,降低了成本,并确保了高质量标准。这项工作介绍了我们在小儿泌尿科使用远程医疗对遗尿症和尿失禁进行随访的经验:方法:我们对意大利都灵玛格丽塔医院(Regina Margherita Children's Hospital)的远程医疗初步经验进行了回顾性分析。该研究包括所有年龄段的患者:共登记了 15 名患者。共进行了 162 次远程会诊。首次就诊时的中位年龄为(9.7±0.66)岁(7-16 岁)。诊断结果如下77/105(67%)为NE,28/105(33%)为LUTS。患者住所与医院之间的平均转诊距离为(46.35±129.37)千米(2-1300 千米不等),转诊时间为(44.21±77.29)分钟(10-780 分钟不等)。在 64/105 例病例中(61%),随访因完全愈合或症状恢复而中断。只有两个病例(2%)由于社会语言障碍而需要转为门诊咨询。146/162个家庭(90%)在每次TOV结束时填写了调查问卷,其中94%的家庭表示非常满意。在对两组患者(G1(52 次远程医疗诊疗)与 G2(25 次面对面诊疗))进行的比较统计分析中,G1 的平均转诊距离为 17.78±7.98 千米(范围:5-35 千米),而 G2 为 7.04±3.35 千米(范围:2.5-14 千米)(P=0.00001)。此外,G1 的就诊前等待时间为 3.96±2.90分钟(范围:0-10 分钟),而 G2 为 26.52±11.22分钟(范围:5-44 分钟)(P=0.00001)。此外,G1 组对行为或药物适应症的依从性更高,在 52 个病例中只有 12 个病例的依从性较低,而 G2 组在 25 个病例中只有 14 个病例的依从性较高(P=0.0091):远程医疗是管理 NE 和 LUTS 治疗随访的适当解决方案和有效工具,可确保适当的质量标准并降低社会成本,如工作日损失和交通费用。实施远程医疗并将其完全融入医疗系统应是我们追求的目标,以便充分利用其所有潜力。
{"title":"The digital era of pediatric urological clinical care: telemedicine for management of lower urinary tract symptoms and nocturnal enuresis - a comprehensive tertiary center insight.","authors":"Elisa Cerchia, Marcello Della Corte, Cristian Fiori, Martina Mandaletti, Elena Ruggiero, Massimo Catti, Simona Gerocarni Nappo","doi":"10.23736/S2724-6051.24.05846-4","DOIUrl":"https://doi.org/10.23736/S2724-6051.24.05846-4","url":null,"abstract":"<p><strong>Background: </strong>Lower urinary tract symptoms (LUTS) and nocturnal enuresis (NE) are complex conditions requiring a long-term follow-up. Telemedicine is an emerging technological tool in the surgical field, and its availability exponentially grew during the COVID-19 pandemic, expanding its application fields, optimizing technical aspects, reducing costs, and ensuring high-quality standards. This work describes our experience with telemedicine in a Division of Pediatric Urology for the follow-up of enuresis and LUTS.</p><p><strong>Methods: </strong>A retrospective analysis of our telemedicine preliminary experience was conducted at Regina Margherita Children's Hospital in Turin, Italy. This study included all the patients aged <18 years who were monitored for enuresis and LUTS through telemedicine between September 1, 2021 and July 31, 2023. Clinical data and outcomes were analyzed, and patients and families were asked to voluntary fill an evaluation questionnaire on their satisfaction. Additionally, we focused on the post COVID-19 period, between September 2022 and July 2023, analyzing the data of two different patients' populations: the first one (G1) of patients choosing telemedicine outpatients visits (TOVs) and the second one (G2) of those choosing a face-to-face visit.</p><p><strong>Results: </strong>One hundred five patients were enrolled. One hundred sixty-two TOVs were performed. The median age at first visit was 9.7±0.66 years (range 7-16 years). Diagnosis were: 77/105 (67%) NE and 28/105 (33%) LUTS. The average referred distance between the patients' residence and the hospital was 46.35±129.37 km (range 2-1300 kilometers) and the time taken to overcome it was 44.21±77.29 minutes (range 10-780 minutes). In 64/105 cases (61%) the follow-up was interrupted for total healing or symptoms resumption. Only two cases (2%) required the conversion to an in-person ambulatory consult, due to a social-linguistic barrier. 146/162 families (90%) filled the survey questionnaire at the end of each TOV, reporting in 94% of cases a high satisfaction level. In the comparative statistical analysis of the two patient groups, G1 (52 telemedicine office visits, [TOVs]) vs. G2 (25 face-to-face visits), the average referred distance was 17.78±7.98 km (range: 5-35 km) for G1, contrasting with 7.04±3.35 km (range: 2.5-14 km) for G2 (P=0.00001). Additionally, the waiting time before the visit was 3.96±2.90 minutes (range: 0-10 minutes) for G1, in contrast to 26.52±11.22 minutes (range: 5-44 minutes) for G2 (P=0.00001). Furthermore, a higher compliance with behavioral or pharmacological indications was observed in the G1 group, exhibiting lower adherence in only 12 out of 52 cases compared to 14 out of 25 cases in G2 (P=0.0091).</p><p><strong>Conclusions: </strong>Telemedicine is a proper solution and an effective tool to manage the therapeutic follow-up of NE and LUTS, ensuring suitable quality standards and reducing social costs, such as the loss of","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":"76 3","pages":"373-381"},"PeriodicalIF":4.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141452138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High-volume surgeons decrease operating time in robot-assisted radical prostatectomy: results in 1229 patients. 高容量外科医生缩短了机器人辅助根治性前列腺切除术的手术时间:1229 例患者的手术结果。
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-06-01 DOI: 10.23736/S2724-6051.24.05617-9
Antonio B Porcaro, Alberto Bianchi, Sebastian Gallina, Emanuele Serafin, Stefano Vidiri, Alessandro Veccia, Riccardo Rizzetto, Francesco Ditonno, Francesca Montanaro, Alberto Baielli, Francesco Artoni, Giulia Marafioti Patuzzo, Andrea Franceschini, Davide Brusa, Alessandro Princiotta, Michele Boldini, Matteo Brunelli, Vincenzo DE Marco, Filippo Migliorini, Maria A Cerruto, Alessandro Antonelli

Background: The aim is to evaluate factors impacting operating time (OT) during robot-assisted radical prostatectomy (RARP) with or without extended pelvic lymph node dissection (ePLND) for prostate cancer.

Methods: Overall, 1289 patients underwent RARP from January 2013 to December 2021. ePLND was performed in 825 cases. Factors potentially associated with OT variations were assessed. Three low-volume (LVS) and two high-volume surgeons (HVS) performed the procedures. A linear regression model was computed to assess associations with OT variations.

Results: When RARP was performed by HVS an OT decrease was observed independently by significant clinical (Body Mass Index [BMI]; prostate volume [PV]) and anatomical/perioperative features (prostate weight [PW]; intraoperative blood loss [BL]) both in clinical (change in OT: -42.979 minutes; 95% CI: -51.789; -34.169; P<0.0001) and anatomical/perioperative models (change in OT: -40.020 minutes; 95% CI: -48.494; -31.587; P<0.0001). A decreased OT was observed in clinical (change in OT: -27.656 minutes; 95% CI: -33.449; -21.864; P<0.0001) and anatomical/perioperative (change in OT: -24.935 minutes; 95% CI: -30.562; -19.308; P<0.0001) models also in case of RARP with ePLND performed by HVS, independently by BMI, PV, PSA as well as for PW, seminal vesicle invasion, positive surgical margins, and BL.

Conclusions: In a tertiary academic referral center, OT decreased when RARP was performed by HVS, independently of adverse clinical and anatomical/perioperative factors. Available OT loads can be planned to optimize waiting lists, teaching tasks, operative costs, and surgeon's volume.

背景:目的:评估影响前列腺癌机器人辅助前列腺癌根治术(RARP)手术时间(OT)的因素:2013年1月至2021年12月期间,共有1289名患者接受了RARP手术。评估了与OT变化可能相关的因素。三名低量外科医生(LVS)和两名高量外科医生(HVS)进行了手术。计算线性回归模型以评估与OT变化的关系:结果:当由HVS实施RARP时,临床(OT变化:-42.979分钟;95% CI:-51.789;-34.169;PC结论)和解剖/围手术期特征(前列腺重量[PW];术中失血量[BL])均明显降低:在一家三级学术转诊中心,使用 HVS 进行 RARP 时,OT 会减少,与不利的临床和解剖/围术期因素无关。可以对可用的加时工作量进行规划,以优化候诊名单、教学任务、手术成本和外科医生的工作量。
{"title":"High-volume surgeons decrease operating time in robot-assisted radical prostatectomy: results in 1229 patients.","authors":"Antonio B Porcaro, Alberto Bianchi, Sebastian Gallina, Emanuele Serafin, Stefano Vidiri, Alessandro Veccia, Riccardo Rizzetto, Francesco Ditonno, Francesca Montanaro, Alberto Baielli, Francesco Artoni, Giulia Marafioti Patuzzo, Andrea Franceschini, Davide Brusa, Alessandro Princiotta, Michele Boldini, Matteo Brunelli, Vincenzo DE Marco, Filippo Migliorini, Maria A Cerruto, Alessandro Antonelli","doi":"10.23736/S2724-6051.24.05617-9","DOIUrl":"https://doi.org/10.23736/S2724-6051.24.05617-9","url":null,"abstract":"<p><strong>Background: </strong>The aim is to evaluate factors impacting operating time (OT) during robot-assisted radical prostatectomy (RARP) with or without extended pelvic lymph node dissection (ePLND) for prostate cancer.</p><p><strong>Methods: </strong>Overall, 1289 patients underwent RARP from January 2013 to December 2021. ePLND was performed in 825 cases. Factors potentially associated with OT variations were assessed. Three low-volume (LVS) and two high-volume surgeons (HVS) performed the procedures. A linear regression model was computed to assess associations with OT variations.</p><p><strong>Results: </strong>When RARP was performed by HVS an OT decrease was observed independently by significant clinical (Body Mass Index [BMI]; prostate volume [PV]) and anatomical/perioperative features (prostate weight [PW]; intraoperative blood loss [BL]) both in clinical (change in OT: -42.979 minutes; 95% CI: -51.789; -34.169; P<0.0001) and anatomical/perioperative models (change in OT: -40.020 minutes; 95% CI: -48.494; -31.587; P<0.0001). A decreased OT was observed in clinical (change in OT: -27.656 minutes; 95% CI: -33.449; -21.864; P<0.0001) and anatomical/perioperative (change in OT: -24.935 minutes; 95% CI: -30.562; -19.308; P<0.0001) models also in case of RARP with ePLND performed by HVS, independently by BMI, PV, PSA as well as for PW, seminal vesicle invasion, positive surgical margins, and BL.</p><p><strong>Conclusions: </strong>In a tertiary academic referral center, OT decreased when RARP was performed by HVS, independently of adverse clinical and anatomical/perioperative factors. Available OT loads can be planned to optimize waiting lists, teaching tasks, operative costs, and surgeon's volume.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":"76 3","pages":"312-319"},"PeriodicalIF":4.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141452135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Da Vinci and Hugo RAS Platforms for robot-assisted partial nephrectomy: a preliminary prospective comparative analysis of the outcomes. 用于机器人辅助肾部分切除术的达芬奇和雨果 RAS 平台:初步前瞻性结果比较分析。
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-06-01 Epub Date: 2024-05-17 DOI: 10.23736/S2724-6051.24.05623-4
Esther García Rojo, Vital Hevia Palacios, Ricardo Brime Menendez, Javier A Feltes Ochoa, Juan Justo Quintas, Fernando Lista Mateos, Karim Touijer, Javier Romero Otero

Background: Robot-assisted partial nephrectomy (RAPN) has emerged as the preferred approach for T1 renal-cell-carcinoma. As new robotic platforms like Hugo RAS emerge, we seek to understand their potential in achieving similar RAPN outcomes as the established Da Vinci system.

Methods: A prospective single-center comparative study was conducted, and 50 patients selected for RAPN were enrolled (25 Da Vinci Xi; 25 Hugo RAS). The choice of robotic system was based solely on hospital logistics criteria. Surgeries were performed by expert surgeons. Demographic data, tumor characteristics, operative details and postoperative outcomes were collected. SPSS version 22.0 was used for statistical analyses.

Results: The average age of patients was 62.52±9.47 years, with no significant differences in median age, sex, and nephrometry scores between groups. Da Vinci group showed a significantly shorter docking time (12.56 vs. 20.08 min; P<0.01), while other intraoperative measures like console time and warm ischemia time were similar. The Hugo RAS group had a shorter renorraphy time (14.33 vs. 18.84 min; P=0.024). Postoperative outcomes and surgical margin positivity showed no significant differences. Each group had one patient (4%) who developed major surgical complications (Clavien IIIa). Trifecta rates were comparable between both groups (Da Vinci 88% vs. Hugo RAS 84%; P=0.93).

Conclusions: Initial findings suggest similar perioperative outcomes for RAPN when using Hugo RAS compared to the Da Vinci system. Further research with long-term follow-up is necessary to evaluate oncological and functional outcomes.

背景:机器人辅助肾部分切除术(RAPN)已成为治疗T1肾细胞癌的首选方法。随着Hugo RAS等新型机器人平台的出现,我们试图了解它们在实现与成熟的达芬奇系统类似的RAPN结果方面的潜力:方法:我们进行了一项前瞻性单中心比较研究,共选取了50例RAPN患者(25例达芬奇Xi;25例雨果RAS)。机器人系统的选择完全基于医院的后勤标准。手术由专家外科医生实施。收集了人口统计学数据、肿瘤特征、手术细节和术后结果。统计分析采用 SPSS 22.0 版:患者的平均年龄为(62.52±9.47)岁,各组的中位年龄、性别和肾功能评分无明显差异。达芬奇组的对接时间明显更短(12.56 分钟对 20.08 分钟;PC 结论:初步研究结果表明,使用雨果RAS与达芬奇系统相比,RAPN的围手术期结果相似。有必要进一步开展长期随访研究,以评估肿瘤和功能方面的结果。
{"title":"Da Vinci and Hugo RAS Platforms for robot-assisted partial nephrectomy: a preliminary prospective comparative analysis of the outcomes.","authors":"Esther García Rojo, Vital Hevia Palacios, Ricardo Brime Menendez, Javier A Feltes Ochoa, Juan Justo Quintas, Fernando Lista Mateos, Karim Touijer, Javier Romero Otero","doi":"10.23736/S2724-6051.24.05623-4","DOIUrl":"10.23736/S2724-6051.24.05623-4","url":null,"abstract":"<p><strong>Background: </strong>Robot-assisted partial nephrectomy (RAPN) has emerged as the preferred approach for T1 renal-cell-carcinoma. As new robotic platforms like Hugo RAS emerge, we seek to understand their potential in achieving similar RAPN outcomes as the established Da Vinci system.</p><p><strong>Methods: </strong>A prospective single-center comparative study was conducted, and 50 patients selected for RAPN were enrolled (25 Da Vinci Xi; 25 Hugo RAS). The choice of robotic system was based solely on hospital logistics criteria. Surgeries were performed by expert surgeons. Demographic data, tumor characteristics, operative details and postoperative outcomes were collected. SPSS version 22.0 was used for statistical analyses.</p><p><strong>Results: </strong>The average age of patients was 62.52±9.47 years, with no significant differences in median age, sex, and nephrometry scores between groups. Da Vinci group showed a significantly shorter docking time (12.56 vs. 20.08 min; P<0.01), while other intraoperative measures like console time and warm ischemia time were similar. The Hugo RAS group had a shorter renorraphy time (14.33 vs. 18.84 min; P=0.024). Postoperative outcomes and surgical margin positivity showed no significant differences. Each group had one patient (4%) who developed major surgical complications (Clavien IIIa). Trifecta rates were comparable between both groups (Da Vinci 88% vs. Hugo RAS 84%; P=0.93).</p><p><strong>Conclusions: </strong>Initial findings suggest similar perioperative outcomes for RAPN when using Hugo RAS compared to the Da Vinci system. Further research with long-term follow-up is necessary to evaluate oncological and functional outcomes.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":" ","pages":"303-311"},"PeriodicalIF":4.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140958845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Minerva Urology and Nephrology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1